1 |
ClinicalTrials.gov (NCT05407961) A Phase 1b, 2-Part, Investigator- and Participant-Blind, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3532226 in Participants With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
|
2 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
|
3 |
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
|
4 |
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.
|
5 |
An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023 Mar;161:170939.
|
6 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
7 |
Clinical pipeline report, company report or official report of Carmot Therapeutics.
|
8 |
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.
|
9 |
ClinicalTrials.gov (NCT04586907) A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
|
10 |
Company report (Roche pipeline: October 16, 2012)
|
11 |
Company report (Roche pipeline: 16 October 2014)
|
|
|
|
|
|
|